Pennies Per Pill: How Direct Primary Care Strips the Markup Out of Generic Medications

Transparent medication pricing starts with an uncomfortable fact: a surprising amount of the price of a generic medication at a retail pharmacy is not the drug. It is the layered margin of wholesale distributors, the chain pharmacy’s overhead and shareholder return, the rebates negotiated with pharmacy benefit managers, and the spread between what a plan pays and what a patient is charged at the counter. The actual cost of producing many common generics — lisinopril, metformin, amlodipine, atorvastatin, hydrochlorothiazide, sertraline — sits at a few cents per pill at the manufacturer. Most of what a patient sees on the price tag is paid to intermediaries who never touched the molecule.

A direct primary care clinic that dispenses medications in-office cuts through that stack. Buying generics at wholesale cost from a licensed distributor and adding a small handling fee, a three-month supply of lisinopril or metformin that runs sixty to eighty dollars at retail can be dispensed for two to five dollars. A typical hypertensive patient on three generics may pay less for a full year of medication than for a single month at the counter elsewhere. The pricing is transparent because there is no insurance claim to obscure it; the patient is the payer, the clinic is the dispenser, and the markup is printed on the receipt.

How does transparent medication pricing improve adherence?

The clinical relevance is that cost is the single best-documented driver of medication non-adherence. Population studies of Medicare beneficiaries and broader literature reviews have repeatedly shown that a meaningful fraction of patients skip doses, split pills, or simply stop refilling when out-of-pocket cost crosses a threshold they cannot absorb without trade-offs against rent, groceries, or other prescriptions. Removing that financial friction is not a luxury feature of direct primary care; it is one of the quietest ways the model meaningfully improves outcomes for patients managing chronic disease on a fixed income.

References:

1. Nekui, F., Galbraith, A. A., Briesacher, B. A., Zhang, F., Soumerai, S. B., Ross-Degnan, D., et al. (2021). Cost-related medication nonadherence and its risk factors among Medicare beneficiaries. Medical Care, 59(1), 13-21.
2. Briesacher, B. A., Gurwitz, J. H., & Soumerai, S. B. (2007). Patients at-risk for cost-related medication nonadherence: A review of the literature. Journal of General Internal Medicine, 22(6), 864-871.